The Global Market for Big Data Technologies and Services is Projected to Reach $60 Billion by 2022

The global Label-Free Detection market is projected to reach US$1.3 billion by 2025, driven by growing drug R&D, rising competitive pressure to reduce cost of drug development and the resulting need for cost-effective and efficient screening technologies. Traditional label-based assays are beset with drawbacks such as high cost associated with label preparation; lower levels of sensitivity and accuracy as measurements are made indirectly using a labeled reactant; risk of certain antigen/antibody reactions not being detected; requires multiple steps and is time consuming; and tendency to modify the physicochemical or binding properties making accurate drug characterization difficult. In this regard, label-free assays for biochemical and cell-based drug discovery is growing in importance due to the many benefits offered such as ability to identify difficult target classes, better insights offered into drug binding kinetics and drug residence time; highly sensitive detection of small molecules, proteins and cells; simple assay procedure; less potential for false positive/negatives; eliminates labelling & reagent costs; aids in high-throughput, independent screening of whole cells; provides new insights into compound action and helps devise better optimization strategies; increased sensitivity and specificity; more accurate quantification of biological responses, among others. All of these benefits are helping replace traditional techniques like radioactive assays, enzyme-labelled assays (ELISA assays), fluorescent labeled assays, luminescent labeled assays, and Chemiluminescence immunoassay (CLIA) with label-free options. Read More…